Est. 2001·3,000+ placements · six offices · four regions
Leadership Changecurated sourcedetected 2026-11-13 · confidence 60%

Last updated

BioNTech: Leadership Change

BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).

Source: HealthCare Middle East & Africa

Who
BioNTech · Biotech & Pharma · Germany
What happened
BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).
When
2026-11-13
So what
A change at the top rarely stays at the top.

The leadership read

A change at the top rarely stays at the top. BioNTech's move reshapes the layer beneath it in Biotech & Pharma as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

Market context: MitchelLake's Talent Market Index sits at 95.4 (Cool), down 5.3 on the prior month; EMEA hiring signal is running rising (+5pts).

BioNTech: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 30 tracked companies.

MitchelLake in this thematic

More signals across Biotech & Pharma

Leadership Change · EMEA

Harbour BioMed →

Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.

Leadership Change · EMEA

BioMarin Pharmaceutical Inc. →

Ian T. Clark elected as new Chair of the Board, replacing retiring Richard A. Meier

Capital Raising · EMEA

Neobe Therapeutics →

UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.

Capital Raising · EMEA

mbiomics →

mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).

Geographic Expansion · EMEA

Bio-Techne →

Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.

Product Launch · EMEA

AviadoBio →

AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.

Where this lands in our work

Weekly briefing

Track companies like BioNTech — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record